The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to compounds of formula (I), wherein R11-31-322232322 R21-31-31-3)-alkyl, R31-322 and a five- or six-membered carbocyclic ring, wherein R3is substituted by one or two substituents R81-31-41-31-31-3-alkyl), wherein each V, U, Q and T are independently from each other selected from C or N, wherein R41-31-31-3-haloalkyl, wherein R51-31-31-3-haloalkyl, wherein R61-31-31-3-haloalkyl, wherein R71-31-31-3-haloalkyl, and pharmaceutical acceptable salts thereof, for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, metabolic dysfunction associated Steatohepatitis (MASH), interstitial lung disease (ILD), decompensated liver cirrhosis and idiopathic pulmonary fibrosis (IPF).
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
3.
4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A
Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A
Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A
and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
4.
COMPOUND FOR USE IN THE TREATMENT OF DEPRESSION, OBSESSIVE-COMPULSIVE DISORDER, POST-TRAUMATIC STRESS DISORDER AND/OR BORDERLINE PERSONALITY DISORDER
The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and/or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and/or its polymorphs.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of
respiratory, inflammatory and autoimmune diseases; providing
of medical and scientific research information in the fields
of respiratory, inflammatory and autoimmune diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of diseases resulting from metabolic disorders and
cardiovascular disorders; providing medical and scientific
research information in the field of prevention and
treatment of diseases resulting from metabolic disorders and
cardiovascular disorders.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of treatment of diseases
resulting from genetic disorders; providing medical and
scientific research information in the field of treatment of
diseases resulting from genetic disorder.
This invention relates to compounds of formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 37/00 - Drugs for immunological or allergic disorders
This invention relates to compounds of formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 37/00 - Drugs for immunological or allergic disorders
This invention relates to compounds of formula (I), wherein these compounds comprise heterocyclic acids at the R4 position in formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of
respiratory, inflammatory and autoimmune diseases; providing
of medical and scientific research information in the fields
of respiratory, inflammatory and autoimmune diseases.
The present invention encompasses heteroaryl substituted 2,6-difluorophenol compounds of formula (I), wherein the groups A1 to A3, and Z have the meanings given in the claims and specification, their use in pharmaceutical compositions which contain these compounds and their use as medicaments, especially to interfere with the progression of liver disease from steatosis to later stages of nonalcoholic steatohepatitis, fibrosis, and cirrhosis.
The present invention encompasses heteroaryl substituted 2,6-difluorophenol compounds of formula (I), wherein the groups A1 to A3, and Z have the meanings given in the claims and specification, their use in pharmaceutical compositions which contain these compounds and their use as medicaments, especially to interfere with the progression of liver disease from steatosis to later stages of nonalcoholic steatohepatitis, fibrosis, and cirrhosis.
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
This invention relates to compounds of formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
15.
FURTHER HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT
This invention relates to compounds of formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
16.
ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT
This invention relates to compounds of formula (I) and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
17.
MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT
This invention relates to compounds of formula (I)
This invention relates to compounds of formula (I)
This invention relates to compounds of formula (I)
and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
18.
RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR
The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
19.
HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT
This invention relates to compounds of formula (1)
This invention relates to compounds of formula (1)
This invention relates to compounds of formula (1)
and their use in the prevention, delaying and/or treatment of diseases or conditions which can be influenced by STING inhibition.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
20.
COMBINATION TREATMENT FOR EYE FIBROSIS AND/OR ANGIOGENESIS
Methods for the diagnosis, treatment and prophylaxis of fibrosis and/or angiogenesis, in particular in the eye, are disclosed. In particular embodiments, the methods employ antagonism of IL-11 mediated signalling and antagonism of angiogenesis. Also provided are combinations comprising an antagonist of IL-11 mediated signalling and an antagonist of an angiogenic factor.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS
This invention generally relates to the field of somatic gene therapy by using viral vectors, and in particular adeno-associated virus (AAV) vectors for the treatment of inherited or acquired diseases. More specifically, the invention relates to a viral capsid protein that provide for a specific transduction of murine endothelial cells for treating or preventing a heart disease in a primate. The viral capsid protein was found to specifically bind to primate heart tissue cells, and in particular primate heart muscle cells, and can be used to provide for an efficient and selective transduction of primate cardiomyocytes and ensure heart tissue-specific expression of one or more transgenes in the primate. The invention further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid with at least one transgene packaged in the capsid. The viral vector is suitable for the therapeutic treatment of a cardiac disorder or disease in a primate. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.
The present disclosure is directed to a bioreactor or fermenter for the culturing of cells or microorganisms in suspension in a liquid medium in industrial scale comprising a vessel containing the culture in a liquid medium having a determined filling height; a stirrer provided in the vessel to stir the liquid medium; a first sparger arranged in the bottom portion of the vessel; and a second or optional more spargers provided above the first sparger to supply additional air bubbles and/or additional oxygen gas bubbles continuously to the liquid medium whereby the second sparger is located at a position in the bioreactor or fermenter above the first sparger in a predefined distance η. It is also described a process for the independent management of dissolved CO2 and O2, by selecting a suitable modified gas flow rate qmod.
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
26.
Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors
The present invention encompasses compounds of formula (I)
The present invention encompasses compounds of formula (I)
wherein the groups R1 to R4, A1, A2, A3, ring system B, V, W, p, q and r have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention pertains to the provision of a vaccine comprising a first component (K) and a second component (V), wherein the first component (K) comprises a complex in which a cell penetrating peptide, an antigenic domain and a TLR agonist are functionally linked and the second component (V) comprises an oncolytic recombinant vesicular stomatitis virus expressing an antigenic domain. The invention further pertains to the use of the inventive vaccine in the treatment of cancer. The invention also provides a recombinant vesicular stomatitis virus expressing an antigenic domain and its use in cancer vaccines.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
28.
BICYCLIC BENZYLAMIDO PYRIDINE DERIVATIVES AS SOS1 INHIBITORS
The present invention encompasses compounds of formula (I) wherein the groups R1to R4, A1, A2, A3, ring system B, V, W, p, q and r have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
29.
COMBINATION OF ZONGERTINIB WITH A SOS1 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with SOS1 inhibitors. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.
This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as psoriasis or psoriatic arthritis, utilizing anti-IL-23A antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Organization and implementation of workshops, seminars, and
training courses in the field of mental health and mental
diseases, including online and via the internet. Scientific medical research service in the field of mental
health and mental diseases; provision of medical and
scientific research information in the fields of mental
health and mental diseases.
32.
GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
33.
Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
The present invention encompasses intermediates for preparing compounds of formula (I)
7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education services, namely, providing workshops, seminars, and training sessions on medical care and health management in the field of chronic metabolic diseases, metabolic disorders, and weight management Providing scientific research information in the field of metabolic diseases, metabolic disorders, and weight management Providing medical information in the field of metabolic diseases, metabolic disorders, and weight management
35.
ALDOSTERONE SYNTHASE INHIBITOR FOR TREATING HEART FAILURE
Disclosed are methods of using an aldosterone synthase inhibitor of formula (1) for treating, reducing the risk of, or delaying the progression of heart failure related disorders. The invention further relates to methods of using Compound 1 in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 9/00 - Drugs for disorders of the cardiovascular system
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Organization and conducting of workshops, seminars, and training sessions on medical care and health management in the field of chronic metabolic diseases, metabolic disorders, and weight management, including online and internet-based formats.
(2) Providing medical and scientific research information in the fields of metabolic diseases, metabolic disorders, and weight management.
(3) Providing information in the field of metabolic diseases and disorders; Providing information in the field of weight management.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Organization and conducting of workshops, seminars, and training sessions on medical care and health management in the field of chronic metabolic diseases, metabolic disorders, and weight management, including online and internet-based formats. Providing medical and scientific research information in the fields of metabolic diseases, metabolic disorders, and weight management. Providing information in the field of metabolic diseases and disorders; Providing information in the field of weight management.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of treatment of diseases resulting from genetic disorders; providing medical and scientific research information in the field of treatment of diseases resulting from genetic disorder.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of diseases resulting from metabolic disorders and cardiovascular disorders; providing medical and scientific research information in the field of prevention and treatment of diseases resulting from metabolic disorders and cardiovascular disorders.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of respiratory, inflammatory and autoimmune diseases; providing of medical and scientific research information in the fields of respiratory, inflammatory and autoimmune diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of respiratory, inflammatory and autoimmune diseases; providing of medical and scientific research information in the fields of respiratory, inflammatory and autoimmune diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of metabolic and cardiovascular diseases; providing medical
and scientific research information in the field of
metabolic and cardiovascular diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of cardiovascular diseases; providing medical and scientific
research information in the field of cardiovascular
diseases.
44.
ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOF
The present disclosure generally relates to anti-CTGF (connective tissue growth factor) antibodies or antigen-binding fragments thereof. Exemplary anti-CTGF antibodies disclosed herein address the need for treatments of conditions modulated by CTGF signaling. In some aspects, the anti-CTGF antibodies or antigen-binding fragments thereof are for diagnostic and/or therapeutic use, for example in a subject in need thereof, such as a human.
The present disclosure generally relates to anti-CTGF (connective tissue growth factor) antibodies or antigen-binding fragments thereof. Exemplary anti-CTGF antibodies disclosed herein address the need for treatments of conditions modulated by CTGF signaling. In some aspects, the anti-CTGF antibodies or antigen-binding fragments thereof are for diagnostic and/or therapeutic use, for example in a subject in need thereof, such as a human.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
46.
NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL
The invention is directed to an improved method of manufacturing the PDE4B-inhibitor of formula XX
The invention is directed to an improved method of manufacturing the PDE4B-inhibitor of formula XX
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
47.
DOSE REGIMEN FOR LONG-ACTING GLP1/GLUCAGON RECEPTOR AGONISTS
The present invention relates to a dosing scheme for long-acting GLP1/glucagon receptor agonists. According to the dosing scheme the interval between two consecutive administrations is defined such that the ratio between the plasma half-life in humans of the agonist and the administration interval is more than 1.
Disclosed are solid forms of an inhibitor of aldosterone synthase (ASi) having the formula The invention also relates to methods of making these solid forms, pharmaceutical compositions comprising these solid forms, and their use for medical conditions responsive to treatment with an inhibitor of aldosterone synthase.
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/00 - Drugs for disorders of the urinary system
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
49.
PIPERIDINYLPHENYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinylphenylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present disclosure provides certain piperidinylphenylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Disclosed are solid forms of an inhibitor of aldosterone synthase (ASi) having the formula (1)
Disclosed are solid forms of an inhibitor of aldosterone synthase (ASi) having the formula (1)
Disclosed are solid forms of an inhibitor of aldosterone synthase (ASi) having the formula (1)
The invention also relates to methods of making these solid forms, pharmaceutical compositions comprising these solid forms, and their use for medical conditions responsive to treatment with an inhibitor of aldosterone synthase.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
52.
PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinyIpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present disclosure provides certain piperidinyIpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of retinal diseases and diabetic eye diseases; providing
medical and scientific research information in the field of
retinal diseases and diabetic eye diseases.
55.
PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of retinal diseases and diabetic eye diseases; providing
medical and scientific research information in the field of
retinal diseases and diabetic eye diseases.
57.
PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
The present disclosure provides certain piperidinylphenylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of metabolic and cardiovascular diseases; providing medical and scientific research information in the field of metabolic and cardiovascular diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of cardiovascular diseases; providing medical and scientific research information in the field of cardiovascular diseases.
60.
ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I
The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I
wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and
wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A,
wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof.
The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I
wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and
wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A,
wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof.
Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III
The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I
wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and
wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A,
wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof.
Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III
The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I
wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and
wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A,
wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof.
Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III
or a pharmaceutically acceptable salt thereof.
The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
The present invention provides a high-throughput method for determining dsRNA editing activity of an A-to-l RNA editing enzyme in a competition assay and particularly this high- throughput method allows for screening of inhibitors of an A-to-l RNA editing enzyme, as well as a medium-throughput method for screening and validating of inhibitors of an A-to-l RNA editing enzyme at single A-to-l editing site. Additionally, a high-throughput method is provided for determining binding of a dsRNA binding protein, particularly an A-to-l RNA editing enzyme, to a dsRNA target, and particularly this high-throughput method can be used for screening or characterizing inhibitors of dsRNA binding proteins.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with an anti-HER2 antibody and/or an anti-HER2 antibody-drug conjugate. Such combination may further comprise an additional anti-cancer medicament. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
66.
NEW GLUTAMINE SYNTHETASE VARIANTS AS SELECTION MARKER
The invention relates to a modified mammalian glutamine synthetase comprising a mutation at amino acid position 10 and/or 298 in a mammalian glutamine synthetase, wherein the mutation is selected from the group consisting of R298K, N10S, N10T and N10Q and to an expression vector, a nucleic acid and a eukaryotic host cell encoding said modified mammalian glutamine synthetase and to its use as a selection marker. The invention further relates to methods for preparing stable cell lines, or for producing a protein of interest using said modified mammalian glutamine synthetase for selection.
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Downloadable and recorded software for providing information on clinical trials Promoting public awareness of clinical trials Educational services, namely, providing web based interactive multimedia software featuring audio and video information for patients on clinical trials
68.
PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
69.
METHOD FOR DETECTING CONTAMINATING CARBOXYLESTERASE ACTIVITY
The present invention relates to a method for detecting carboxylesterase activity of contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture comprising contacting the sample with the hydrophilic substrate HPTS ester and optionally in addition separately contacting the sample with a lipophilic substrate 4-MU ester and detecting the carboxylesterase and optionally lipase activity of the at least one contaminating host cell protein using the hydrophilic and optionally lipophilic substrate by detecting the fluorescence intensity of the released chromophore. Further provided is a method for manufacturing a recombinant protein of interest comprising using the method for detecting carboxylase activity of a contaminating host cell protein in a sample comprising a recombinant protein of interest produced in a eukaryotic cell in cell culture using a hydrophilic substrate and optionally further a lipophilic substrate for determining contaminating carboxylesterase and/or lipase activity in the sample comprising the recombinant protein of interest during manufacture.
The present invention refers to the combination of the HER2 tyrosine kinase zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.
NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL
The invention refers to an improved method of manufacturing Intermediate (VIII), wherein in step a) 5-Chloro-2-iodo-pyrimidine and boc-boronic ester (V) are reacted in the presence of the catalyst bis(amphos)palladium-II-chloride to yield Intermediate (VI) and wherein in step b) Intermediate (VI) is hydrogenated to yield the non-isolated Intermediate (VII) and wherein in step c) the non-isolated Intermediate (VII) is reacted with hydrochloric acid to yield Intermediate (VIII). The invention further related to a method of manufacturing Intermediate (XVIII), which is substantially enantiomerically pure with a content of ≤ 0.5 % of the unwanted enantiomer ent-XVII, preferably with an enantiomeric excess over the unwanted enantiomer ent-XVII of at least 99.88 %, and with a content of less than 30 ppm of titanium, whereby this substantially enantiomerically pure Intermediate (XVII) was manufactured by steps a), b), c) and d) as described in claim 18. The invention additionally refers to a method of recrystallizing Intermediate (XIX) from a mixture of 5 VP of n-propanol and of 1.25 VP of water to yield the PDE4B-inhibitor of formula (XX) in the crystalline form B.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with an anti-HER2 antibody and/or an anti-HER2 antibody-drug conjugate. Such combination may further comprise an additional anti-cancer medicament. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
73.
CANCER COMBINATION THERAPY USING ZONGERTINIB AND A KRAS G12C INHIBITOR
The present invention refers to the combination of the HER2 tyrosine kinase zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accordingly, compounds for use, methods of prevention and/or treatment, uses, pharmaceutical compositions and kits related to the combination are herewith provided.
The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.
The present invention relates to a measuring arrangement with a flow cell. The flow cell is arranged in such a way that the fluidic sample flows from bottom to top through the flow cell. The fluidic sample flows through the flow cell within a residence time which is greater than 1 second. Additionally or alternatively, the measuring arrangement comprises a pumping device to pump the fluid forwards and backwards through the flow cell during measurement. It is possible to reduce and/or prevent air bubbles in the flow cell. In this way it is possible to reduce and/or prevent the negative influence of gas bubbles on the measurement.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Organization and implementation of workshops, seminars, and training courses in the field of mental health and mental diseases, including online and via the internet.
(2) Scientific medical research service in the field of mental health and mental diseases; provision of medical and scientific research information in the fields of mental health and mental diseases.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Organization and implementation of workshops, seminars, and training courses in the field of mental health and mental diseases, including online and via the internet. Scientific medical research service in the field of mental health and mental diseases; provision of medical and scientific research information in the fields of mental health and mental diseases.
The present invention generally relates to pharmaceutical formulations which are useful for treating acute coronary syndrome. More specifically, the invention pertains to a novel pharmaceutical formulation which comprises a myeloid-derived growth factor (MYDGF) protein which is useful for treating a myocardial infarction in a subject in need thereof. The pharmaceutical formulation of the invention provides a significantly improved long-term stability compared to commonly used formulations. In addition, the pharmaceutical formulation of the invention allows an easy lyophilisation and reconstitution without any significant loss of the therapeutically active protein. The invention also pertains to a formulation for use in a method for treating a myocardial infarction in a subject in need thereof. The method comprises an intravenous administration of a MYDGF protein to the subject on top of standard of care.
The present invention generally relates to pharmaceutical formulations which are useful for treating acute coronary syndrome. More specifically, the invention pertains to a novel pharmaceutical formulation which comprises a myeloid-derived growth factor (MYDGF) protein which is useful for treating a myocardial infarction in a subject in need thereof. The pharmaceutical formulation of the invention provides a significantly improved long-term stability compared to commonly used formulations. In addition, the pharmaceutical formulation of the invention allows an easy lyophilisation and reconstitution without any significant loss of the therapeutically active protein. The invention also pertains to a formulation for use in a method for treating a myocardial infarction in a subject in need thereof. The method comprises an intravenous administration of a MYDGF protein to the subject on top of standard of care.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of retinal diseases and diabetic eye diseases; providing medical and scientific research information in the field of retinal diseases and diabetic eye diseases.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of medicine; providing medical and scientific research information in the field of pharmaceuticals, namely, providing information relating to specific pharmaceutical trials and clinical trials; all of the foregoing excluding the provision of an on-line searchable database and excluding information for use at the point of patient care and in pharmacies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment
of metabolic and cardiovascular diseases; providing medical
and scientific research information in the field of
metabolic and cardiovascular diseases.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software applications for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders; Downloadable computer software for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders; Downloadable computer application software for mobile phones, namely, software for assisting patients with the management of symptoms of central nervous system diseases and disorders and mental illness and disorders Medical and scientific research in the field of mental health; providing medical research and scientific research information in the field of mental illness and disorders Health care services, namely, therapeutic services for patients with symptoms of diseases and disorders of the central nervous system; Health care services, namely, therapeutic services for patients to support mental health
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research in the field of prevention and treatment of retinal diseases and diabetic eye diseases; providing medical and scientific research information in the field of retinal diseases and diabetic eye diseases.
85.
HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER
The present invention encompasses compounds of the formula (I), wherein R1, R2.a, R2.b, R3.a, R3.b, R4.a, R4.b, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, Rx, n and Q have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
The present invention encompasses compounds of the formula (I), wherein R1, R2.a, R2.b, R3.a, R3.b, R4.a, R4.b, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, Rx, n and Q have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a novel N-[(Pyrimidinylamino) propanyl]-arylcarboxamide derivative, its pharmaceutical compositions containing it and its use in therapy, particularly in the treatment or prevention of conditions having an association with the GPR88-receptor.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
87.
BISPECIFIC ANTIBODIES AGAINST CD277 AND A TUMOR-ANTIGEN
The present invention relates to bispecific antibodies binding to CD277 and to a human tumor-antigen. The present invention relates also to polynucleotides encoding such bispecific antibodies and to vectors and host cells comprising such polynucleotides. In addition, the present invention relates to methods for producing such antibodies and to methods of using such antibodies in the treatment of diseases and their therapeutic use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical and scientific research in the fields of respiratory
diseases, inflammatory diseases and autoimmune diseases;
providing medical and scientific research information in the
field of respiratory diseases, inflammatory diseases and
autoimmune diseases.
90.
METHOD FOR DETERMINING THE SHEAR STRESS SENSITIVITY OF CELLS DURING A CULTIVATION PROCESS
The present disclosure is directed to a method for determining the shear stress sensitivity of eukaryotic or prokaryotic cells in a shear stress sensitivity device (100) during a cultivation process, comprising: (1) providing a shear stress sensitivity device (100), (2) selecting cells, liquid culture medium, cultivation mode and conditions; (3) selecting one, two or three stress parameters; (4) characterizing the shear stress sensitivity device (100) for the maximum shear stress by a calibration method; (5) performing the same cultivation process several times and measuring one or more performance characteristics of the cells during each run and generating a curve for each performance characteristic in each run over time; (6) performing the cultivation process as a control having a lower maximum shear stress than in step (5); and (7) selecting the curve from the set of curves of step (5) that is closest to the control curve while obtaining the shear stress sensitivity or limit for the cells.
[00121] The present invention relates to a label-free, high throughput method for determining an infectious virus titer in an aqueous sample comprising infectious virus, wherein the method comprises detecting the kinetics of morphological cell alteration, such as cell rounding, following viral infection, determining a parameter defining the curve of the morphological cell alteration as a function of time post infection and determining the infectious virus titer based on a standard curve of the infectious virus at a known infectious titer.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
92.
BISPECIFIC AND TETRAVALENT CD137 AND FAP MOLECULES FOR THE TREATMENT OF CANCER
This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
93.
IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS
The present invention relates to a method for identification of common patient-spanning tumor-specific T cell receptors (TCRs) and their corresponding antigens. The invention also relates to these TCR sequences, a nucleic acid encoding the TCR, and a T cell comprising the TCR and/or the encoding nucleic acid.
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software and downloadable mobile
applications for assisting patients with symptoms of central
nervous system diseases and disorders; downloadable computer
software and downloadable mobile applications to assist
patients with mental illness and disorders. Therapeutic services for patients with symptoms of diseases
and disorders of the central nervous system; therapeutic
services for patients to support mental health.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Organization and conducting of workshops, seminars and
training courses for medical care, prevention, and
healthcare management in the field of mental health
disorders, including online and via the internet. Medical services in the field of mental health disorders;
providing medical support in the monitoring of patients with
mental health disorders; health counselling, individual
medical counseling services provided to patients in the
field of mental health disorders.
96.
SYNTHESIS OF MORPHOLINE DERIVATIVES AND COMPOUNDS THEREFORE
C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
